MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Oseltamivir acid

CAS No. : 187227-45-8

MCE 站：Oseltamivir acid

产品活性：Oseltamivir acid (GS 4071)，Oseltamivir phosphate 的活性代谢产物, 是流感病毒神经氨酸酶 (IC₅₀=2 nM) 的口服生物有效的，选择性的抑制剂，对流感病毒 A 和 B 都有活性。

研究领域：Anti-infection  |  Metabolic Enzyme/Protease

作用靶点：Influenza Virus  |  Drug Metabolite

In Vitro: Oseltamivir acid inhibits virus replication in vitro and in vivo. Influenza B and A/H1N1 viruses appeare to be sensitive to Oseltamivir (mean B IC₅₀ value: 13 nM; mean H1N1 IC₅₀ value: 1.34 nM), while A/H1N2 and A/H3N2 viruses are more sensitive to Oseltamivir (mean H3N2 IC₅₀ value: 0.67 nM; mean H1N2 IC₅₀ value: 0.9 nM).
In neuraminidases inhibition assays with influenza A viruses, the IC₅₀ of RWJ-270201 (approximately 0.34 nM) is comparable to that of Oseltamivir carboxylate (0.45 nM) For influenza B virus isolates, the IC₅₀ of RWJ-270201 (1.36 nM) is comparable to that of Zanamivir (2.7 nM) and less than that of Oseltamivir carboxylate (8.5 nM).

In Vivo: Oseltamivir (0.1, 1, or 10 mg/kg/day, twice daily by oral gavage) produces a dose-dependent antiviral effect against Vietnam/1203/04 (VN1203/04) virus. The 5-day regimen at 10 mg/kg/day protects 50% of mice; deaths in this treatment group are delayed and indicated the replication of residual virus after the completion of treatment. Eight-day regimens improved Oseltamivir efficacy, and dosages of 1 and 10 mg/kg/day significantly reduced virus titers in organs and provided 60% and 80% survival rates, respectively.
In the pharmacokinetic study, after the oral administration of 1,000 mg/kg Oseltamivir, peak plasma concentrations are reached at 2 h postdose for Oseltamivir and 8 h for Oseltamivir carboxylate (OC). Rats are exposed to Oseltamivir over the whole sampling interval and had a ~2.7-fold-higher rate of exposure to OC than Oseltamivir. In CSF, peak concentrations are reached at 2 h postdose for Oseltamivir and 6 h for OC. CSF/plasma exposure ratios (AUC_{0-8 h}) are ~0.07 for Oseltamivir and 0.007 for OC. In perfused brain samples, peak concentrations are reached at 8 h postdose for Oseltamivir and 6 h for OC. Brain/plasma exposure ratios (AUC_{0-8 h}) of ~0.12 for Oseltamivir and 0.01 for OC are recorded. Corresponding CSF/brain exposure ratios ranged between ~0.55 and 0.64 for both analytes. A further group of animals that received a single oral administration of Oseltamivir at a lower dose produced similar results.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Antiviral Compound Library  |  CNS-Penetrant Compound Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Acetylcysteine  |  U0126-EtOH  |  Tunicamycin  |  Clozapine N-oxide  |  Vadimezan  |  Favipiravir  |  Curcumin  |  Camptothecin  |  Aprotinin  |  Geldanamycin  |  Emricasan  |  Rifampicin  |  Baicalein  |  Oseltamivir phosphate  |  Mycophenolic acid  |  AG-1478  |  AEBSF hydrochloride  |  Urolithin A  |  α-Vitamin E  |  Nitazoxanide  |  GSK 650394  |  Umifenovir hydrochloride  |  Spermine  |  Isoliquiritigenin  |  Oxymatrine  |  6-Diazo-5-oxo-L-nor-Leucine  |  Pimodivir  |  Pentagalloylglucose  |  Naringenin  |  Catechin

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。